Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
550 participants
OBSERVATIONAL
2026-01-07
2029-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Observational Study on ES-SCLC
NCT07173946
A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC
NCT06503042
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
NCT04263688
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
NCT07215026
Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC
NCT07186855
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Patients starting first line pembrolizumab or pembrolizumab in combination with a platinum doublet
No interventions assigned to this group
Cohort 2
Patients with KRASG12D mutation starting first or later line of therapy
No interventions assigned to this group
Cohort 3
Patients planned to have second line docetaxel or docetaxel in combination with ramucirumab with tumor without alterations in KRAS, EGFR, ALK, or ROS1
No interventions assigned to this group
Cohort 4
Patients with PD-L1 \> 50% treated with single agent immuno-oncology therapy (IO) or dual IO agents as first line treatment.
No interventions assigned to this group
Cohort 5
Patients with PD-L1 \< 50% without alterations in KRAS, EGFR, ALK, or ROS1
No interventions assigned to this group
Cohort 6
Patients with documented KRAS G12C mutation
No interventions assigned to this group
Cohort 7
Patients with non-G12C and non-G12D KRAS mutations
No interventions assigned to this group
Cohort 8
Patients with EGFR mutations with prior treatment with osimertinib in combination with chemotherapy or lazertinib in combination with amivantamab
No interventions assigned to this group
Cohort 9
Patients initiating single agent docetaxel or docetaxel and ramucirumab as third line of therapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
2. Actively on a clinical trial of an investigational agent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
N-Power Medicine
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Cancer Care
Monterey, California, United States
Bayhealth Medical Center, Kent Campus
Dover, Delaware, United States
Bayhealth Medical Center- Sussex Campus
Milford, Delaware, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NPM-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.